These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25131421)

  • 41. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression.
    Heselmeyer-Haddad K; Berroa Garcia LY; Bradley A; Ortiz-Melendez C; Lee WJ; Christensen R; Prindiville SA; Calzone KA; Soballe PW; Hu Y; Chowdhury SA; Schwartz R; Schäffer AA; Ried T
    Am J Pathol; 2012 Nov; 181(5):1807-22. PubMed ID: 23062488
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.
    Krohn A; Seidel A; Burkhardt L; Bachmann F; Mader M; Grupp K; Eichenauer T; Becker A; Adam M; Graefen M; Huland H; Kurtz S; Steurer S; Tsourlakis MC; Minner S; Michl U; Schlomm T; Sauter G; Simon R; Sirma H
    J Pathol; 2013 Sep; 231(1):130-41. PubMed ID: 23794398
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
    Huang KC; Evans A; Donnelly B; Bismar TA
    Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.
    Schelling LA; Williamson SR; Zhang S; Yao JL; Wang M; Huang J; Montironi R; Lopez-Beltran A; Emerson RE; Idrees MT; Osunkoya AO; Man YG; Maclennan GT; Baldridge LA; Compérat E; Cheng L
    Hum Pathol; 2013 Oct; 44(10):2227-33. PubMed ID: 23850495
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.
    Pust A; Kylies D; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Salomon G; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Krech T; Schlomm T; Melling N
    Hum Pathol; 2016 Feb; 48():102-10. PubMed ID: 26614400
    [TBL] [Abstract][Full Text] [Related]  

  • 47. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.
    Perner S; Mosquera JM; Demichelis F; Hofer MD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; De Marzo AM; Rubin MA
    Am J Surg Pathol; 2007 Jun; 31(6):882-8. PubMed ID: 17527075
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with PTEN loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.
    Bakker A; Slack JC; Palanisamy N; Carskadon S; Ghosh S; Khalifeh I; Bismar TA
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3721-3728. PubMed ID: 35982181
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
    Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
    BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients.
    Qi M; Yang X; Zhang F; Lin T; Sun X; Li Y; Yuan H; Ren Y; Zhang J; Qin X; Han B
    PLoS One; 2014; 9(2):e84959. PubMed ID: 24516518
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.
    Troyer DA; Jamaspishvili T; Wei W; Feng Z; Good J; Hawley S; Fazli L; McKenney JK; Simko J; Hurtado-Coll A; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Brooks JD; Squire JA
    Prostate; 2015 Aug; 75(11):1206-15. PubMed ID: 25939393
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene.
    Ribeiro FR; Paulo P; Costa VL; Barros-Silva JD; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
    PLoS One; 2011; 6(7):e22317. PubMed ID: 21814574
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features.
    Fine SW; Gopalan A; Leversha MA; Al-Ahmadie HA; Tickoo SK; Zhou Q; Satagopan JM; Scardino PT; Gerald WL; Reuter VE
    Mod Pathol; 2010 Oct; 23(10):1325-33. PubMed ID: 20562851
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate.
    Bettendorf O; Schmidt H; Staebler A; Grobholz R; Heinecke A; Boecker W; Hertle L; Semjonow A
    Genes Chromosomes Cancer; 2008 Jul; 47(7):565-72. PubMed ID: 18383208
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.
    Rajput AB; Miller MA; De Luca A; Boyd N; Leung S; Hurtado-Coll A; Fazli L; Jones EC; Palmer JB; Gleave ME; Cox ME; Huntsman DG
    J Clin Pathol; 2007 Nov; 60(11):1238-43. PubMed ID: 17259299
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer.
    Schroeder C; Grell J; Hube-Magg C; Kluth M; Lang D; Simon R; Höflmayer D; Minner S; Burandt E; Clauditz TS; Büscheck F; Jacobsen F; Huland H; Graefen M; Schlomm T; Sauter G; Steurer S
    BMC Cancer; 2019 Mar; 19(1):193. PubMed ID: 30823906
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers.
    Guo CC; Wang Y; Xiao L; Troncoso P; Czerniak BA
    Hum Pathol; 2012 May; 43(5):644-9. PubMed ID: 21937078
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy.
    Bramhecha YM; Rouzbeh S; Guérard KP; Scarlata E; Brimo F; Chevalier S; Hamel L; Aprikian AG; Lapointe J
    Mod Pathol; 2019 Jan; 32(1):128-138. PubMed ID: 30140035
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy.
    Zafarana G; Ishkanian AS; Malloff CA; Locke JA; Sykes J; Thoms J; Lam WL; Squire JA; Yoshimoto M; Ramnarine VR; Meng A; Ahmed O; Jurisica I; Milosevic M; Pintilie M; van der Kwast T; Bristow RG
    Cancer; 2012 Aug; 118(16):4053-62. PubMed ID: 22281794
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR.
    Simper NB; Jones CL; MacLennan GT; Montironi R; Williamson SR; Osunkoya AO; Wang M; Zhang S; Grignon DJ; Eble JN; Tran T; Wang L; Baldrige LA; Cheng L
    Hum Pathol; 2015 Jun; 46(6):805-12. PubMed ID: 25870120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.